Matches in Nanopublications for { ?s ?p "[Angiotensin II type I receptor and miR-155 in endometrial cancers: synergistic antiproliferative effects of anti-miR-155 and losartan on endometrial cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 14 of
14
with 100 items per page.
- assertion description "[Angiotensin II type I receptor and miR-155 in endometrial cancers: synergistic antiproliferative effects of anti-miR-155 and losartan on endometrial cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Angiotensin II type I receptor and miR-155 in endometrial cancers: synergistic antiproliferative effects of anti-miR-155 and losartan on endometrial cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Angiotensin II type I receptor and miR-155 in endometrial cancers: synergistic antiproliferative effects of anti-miR-155 and losartan on endometrial cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP995529.RAClxYDeCesa4k8jNMEUxyaInRoJJpT0zxTEhcg2KjyG0130_assertion description "[Angiotensin II type I receptor and miR-155 in endometrial cancers: synergistic antiproliferative effects of anti-miR-155 and losartan on endometrial cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP995529.RAClxYDeCesa4k8jNMEUxyaInRoJJpT0zxTEhcg2KjyG0130_provenance.
- NP995173.RA6Gl7PHdTW5EHNRBpNdUjGm-HCrKGc0X3q8mvu07i2hw130_assertion description "[Angiotensin II type I receptor and miR-155 in endometrial cancers: synergistic antiproliferative effects of anti-miR-155 and losartan on endometrial cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP995173.RA6Gl7PHdTW5EHNRBpNdUjGm-HCrKGc0X3q8mvu07i2hw130_provenance.
- NP995415.RAU8qmGZJJWKRzIRtRMDkscqk6S5mdQjGXBAxHogUUHG0130_assertion description "[Angiotensin II type I receptor and miR-155 in endometrial cancers: synergistic antiproliferative effects of anti-miR-155 and losartan on endometrial cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP995415.RAU8qmGZJJWKRzIRtRMDkscqk6S5mdQjGXBAxHogUUHG0130_provenance.
- NP976798.RA06WqMXO-uThq4xhH0muJAPAioBPVHfFH-KYh2dWs4Xk130_assertion description "[Angiotensin II type I receptor and miR-155 in endometrial cancers: synergistic antiproliferative effects of anti-miR-155 and losartan on endometrial cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP976798.RA06WqMXO-uThq4xhH0muJAPAioBPVHfFH-KYh2dWs4Xk130_provenance.
- NP976800.RA_cRwcUwSLwzXbKR-ELj9qbISiH4_HkuhMWAoShbW9Tc130_assertion description "[Angiotensin II type I receptor and miR-155 in endometrial cancers: synergistic antiproliferative effects of anti-miR-155 and losartan on endometrial cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP976800.RA_cRwcUwSLwzXbKR-ELj9qbISiH4_HkuhMWAoShbW9Tc130_provenance.
- NP976802.RAaNTpspLLF2ZHJoFLVhuItqwWNUx0JmFEJ71_kMSdC-c130_assertion description "[Angiotensin II type I receptor and miR-155 in endometrial cancers: synergistic antiproliferative effects of anti-miR-155 and losartan on endometrial cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP976802.RAaNTpspLLF2ZHJoFLVhuItqwWNUx0JmFEJ71_kMSdC-c130_provenance.
- assertion description "[Angiotensin II type I receptor and miR-155 in endometrial cancers: synergistic antiproliferative effects of anti-miR-155 and losartan on endometrial cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Angiotensin II type I receptor and miR-155 in endometrial cancers: synergistic antiproliferative effects of anti-miR-155 and losartan on endometrial cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Angiotensin II type I receptor and miR-155 in endometrial cancers: synergistic antiproliferative effects of anti-miR-155 and losartan on endometrial cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP230291.RAvVh5Jis8uLpBF9M6eaw34n0vyxXokJwJ7wBLedpnaMw130_assertion description "[Angiotensin II type I receptor and miR-155 in endometrial cancers: synergistic antiproliferative effects of anti-miR-155 and losartan on endometrial cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP230291.RAvVh5Jis8uLpBF9M6eaw34n0vyxXokJwJ7wBLedpnaMw130_provenance.
- NP976804.RAlb5EaA88h9Nbc45L54JtI5SGGniOxYtfY8htLRHM3qM130_assertion description "[Angiotensin II type I receptor and miR-155 in endometrial cancers: synergistic antiproliferative effects of anti-miR-155 and losartan on endometrial cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP976804.RAlb5EaA88h9Nbc45L54JtI5SGGniOxYtfY8htLRHM3qM130_provenance.